Revving up the immune engine in cHL

Abstract

In this issue of Blood, Armand et al report on a clinical trial of pembrolizumab, an immunoglobulin G4 anti-programmed cell death-1 (anti-PD-1) antibody, administered to patients as consolidation or maintenance therapy after autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL). 1 10. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.